慢性癌痛治疗药物的比较疗效:贝叶斯网络荟萃分析
该贝叶斯网络荟萃分析纳入81项随机对照试验共10,003例患者,比较11类药物对慢性癌痛的疗效。全局疗效排名前三的类别为非阿片类镇痛药、非甾体抗炎药和阿片类药物;在降低疼痛强度方面,没有哪一类药物优于安慰剂,但齐考诺肽、地佐辛和双氯芬酸等个别干预优于安慰剂。作者认为某些非阿片类镇痛药和非甾体抗炎药可与阿片类药物同样有效地治疗慢性癌痛。
要点
- 全局疗效排名前三的类别为非阿片类镇痛药(网络OR 0.30)、非甾体抗炎药(网络OR 0.44)和阿片类药物(网络OR 0.49)。
- 降低疼痛强度方面,没有哪一类药物优于安慰剂,但齐考诺肽、地佐辛和双氯芬酸等个别干预优于安慰剂。
- 作者认为某些非阿片类镇痛药和非甾体抗炎药可与阿片类药物同样有效地治疗慢性癌痛。
核心结论
- 当前慢性癌痛治疗方案之间存在显著疗效差异。
- 作者认为某些非阿片类镇痛药和非甾体抗炎药可与阿片类药物同样有效地治疗慢性癌痛。
研究设计与样本
- 系统检索电子数据库,纳入比较任何全身性药物干预和/或其联合方案治疗慢性癌痛的随机对照试验(RCT)。
- 共纳入81项RCT、10,003例患者,涉及11类药物。
- 主要结局为全局疗效,以比值比(OR)报告;次要结局为疼痛强度变化,以标准化均数差(SMD)报告。
- 大多数RCT(80%)显示低偏倚风险。
主要发现
- 全局疗效排名前三的类别为非阿片类镇痛药(网络OR 0.30;95%可信区间[CrI] 0.13至0.67)、非甾体抗炎药(网络OR 0.44;95%CrI 0.22至0.90)和阿片类药物(网络OR 0.49;95%CrI 0.27至0.86)。
- 全局疗效排名前三的干预为利多卡因(网络OR 0.04;95%CrI 0.01至0.18;累积排名曲线下面积[SUCRA]评分98.1)、可待因加阿司匹林(网络OR 0.22;95%CrI 0.08至0.63;SUCRA评分81.1)和普瑞巴林(网络OR 0.29;95%CrI 0.08至0.92;SUCRA评分73.8)。
- 在降低疼痛强度方面,没有哪一类药物优于安慰剂。
- 以下干预在降低疼痛强度方面优于安慰剂:齐考诺肽(网络SMD -24.98;95%CrI -32.62至-17.35;SUCRA评分99.8)、地佐辛(网络SMD -13.56;95%CrI -23.37至-3.69;SUCRA评分93.5)和双氯芬酸(网络SMD -11.22;95%CrI -15.91至-5.80;SUCRA评分92.9)。
关键数值与推荐
- 全局疗效排名前三的类别:非阿片类镇痛药网络OR 0.30(95%CrI 0.13至0.67)、非甾体抗炎药网络OR 0.44(95%CrI 0.22至0.90)、阿片类药物网络OR 0.49(95%CrI 0.27至0.86)。
- 全局疗效排名前三的干预:利多卡因网络OR 0.04(95%CrI 0.01至0.18;SUCRA评分98.1)、可待因加阿司匹林网络OR 0.22(95%CrI 0.08至0.63;SUCRA评分81.1)、普瑞巴林网络OR 0.29(95%CrI 0.08至0.92;SUCRA评分73.8)。
- 降低疼痛强度优于安慰剂的干预:齐考诺肽网络SMD -24.98(95%CrI -32.62至-17.35;SUCRA评分99.8)、地佐辛网络SMD -13.56(95%CrI -23.37至-3.69;SUCRA评分93.5)、双氯芬酸网络SMD -11.22(95%CrI -15.91至-5.80;SUCRA评分92.9)。
临床怎么用
- 作者认为某些非阿片类镇痛药和非甾体抗炎药可与阿片类药物同样有效地治疗慢性癌痛。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Opioids are the primary choice for managing chronic cancer pain. However, many nonopioid therapies are currently prescribed for chronic cancer pain with little published evidence comparing their efficacy. METHODS: Electronic databases were searched for randomized controlled trials (RCTs) comparing any systemic pharmaceutical intervention and/or combination thereof in treating chronic cancer pain. The primary outcome was global efficacy reported as an odds ratio (OR). The secondary outcome was change in pain intensity reported as a standardized mean difference (SMD). RESULTS: We included 81 RCTs consisting of 10,003 patients investigating 11 medication classes. Most RCTs (80%) displayed low risk of bias. The top-ranking classes for global efficacy were nonopioid analgesics (network OR, 0.30; 95% credibility interval [CrI], 0.13 to 0.67), nonsteroidal anti-inflammatory drugs (network OR, 0.44; 95% CrI, 0.22 to 0.90), and opioids (network OR, 0.49; 95% CrI, 0.27 to 0.86), whereas the top-ranked interventions were lidocaine (network OR, 0.04; 95% CrI, 0.01 to 0.18; surface under the cumulative ranking curve analysis [SUCRA] score, 98.1), codeine plus aspirin (network OR, 0.22; 95% CrI, 0.08 to 0.63; SUCRA score, 81.1), and pregabalin (network OR, 0.29; 95% CrI, 0.08 to 0.92; SUCRA score, 73.8). In terms of reducing pain intensity, we found that no class was superior to placebo, whereas the following top-ranked interventions were superior to placebo: ziconotide (network SMD, -24.98; 95% CrI, -32.62 to -17.35; SUCRA score, 99.8), dezocine (network SMD, -13.56; 95% CrI, -23.37 to -3.69; SUCRA score, 93.5), and diclofenac (network SMD, -11.22; 95% CrI, -15.91 to -5.80; SUCRA score, 92.9). CONCLUSION: There are significant differences in efficacy among current regimens for chronic cancer pain. Our evidence suggests that certain nonopioid analgesics and nonsteroidal anti-inflammatory drugs can serve as effectively as opioids in managing chronic cancer pain.
引用
- Huang R, Jiang L, Cao Y, et al. Comparative Efficacy of Therapeutics for Chronic Cancer Pain: A Bayesian Network Meta-Analysis. J Clin Oncol. 2019. PMID: 30939089. doi:10.1200/JCO.18.01567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。